

**Serial No.**

**10/525,643**

**Applicant**

(Use several sheets if necessary)


**COUKOS et al.**

1644

Filing Date

~~TC/A.U.~~

**March 6, 2006**



## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

/M.D./	Cosman et al, "ULBPs, Novel MHC Class I-Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor", <i>Immunity</i> 14:123-133 (2001)
↓	Girardi et al, "Regulation of Cutaneous Malignancy by $\gamma\delta$ T Cells", <i>Science</i> 294:605-609 (2001)
↓	Moretta et al, "Activating Receptors And Coreceptors Involved In Human Natural Killer Cell-Mediated Cytolysis", <i>Annu. Rev. Immunol.</i> 19:197-223 (2001)
↓	Pardoll, "Stress, NK Receptors, and Immune Surveillance", <i>Science</i> 294:534 (2001)
↓	Sutherland et al, "The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions", <i>Immunological Reviews</i> 181:185-192 (2001)
/M.D./	Diefenbach et al, "Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity", 413:165-171 (2001)

\*Examiner

/Marianne DiBrino/

Date Considered

03/12/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.